Thrombosis and Haemostasis
Author Interview
Original Article
Ramón Lecumberri, PEDRO RUIZ-ARTACHO, Inna Tzoran, Benjamin Brenner, Dominique FARGE BANCEL, Cihan Ay, Vladimir Rosa, Francisco Iria, Luis Hernández-Blasco, Javier Trujillo Santos, Manuel Monreal
Thromb Haemost
DOI: 10.1055/a-1777-4006
T&H
Why did you (and your colleagues) write this paper? What was its main purpose?
RAMÓN LECUMBERRI
Cancer is a complex and heterogeneous disease. Therefore, the outcome of cancer-associated venous thromboembolism (CAT) could vary between different cancer types. In addition, knowledge about the prognosis of CAT among patients with hematologic malignancies was scarce. The aim of our study was to compare clinical characteristics, management and outcomes of patients with CAT in the setting of a hematologic cancer vs solid cancer.
T&H
What are the main conclusions?
RAMÓN LECUMBERRI
Hematologic patients with CAT, particularly those with multiple mieloma, have lower incidence of recurrent thrombosis, major bleeding a overall death than patients with solid cancers.
T&H
What are the paper's implications? - to the public? -to medical professionals?
RAMÓN LECUMBERRI
The work provides robust estimates of the incidence of complications in patients with venous thromboembolism associated to a hematologic malignancy. Our results can be useful for the interpretation of recent clinical trials on anticoagulant therapy in patients with cancer-associated thrombosis.
T&H
Are the findings clinically significant? Should the findings change practice?
RAMÓN LECUMBERRI
The results have been obtained from a very large series of patients. Given the better outcome of CAT in patients with hematologic malignancies, the hypothesis of a differential management is raised, although this should be evaluated in appropriately designed clinical trials.
